In the Claims

Applicant has submitted a new complete claim set showing marked up claims with insertions indicated by underlining and deletions indicated by strikeouts and/or double bracketing.

Please cancel claims 5, 6, 7, 14, 18, 29, 47, 49-53, 74, 79, 140, and 148 without prejudice or disclaimer.

Please amend pending claims 1, 3, 39, and 44 as noted below.

1. (Currently Amended) A method for decreasing mitochondrial membrane potential in a tumor cell, expressing MHC class II HLA-DR on the surface, comprising

administering an MHC class II HLA-DR ligand to the tumor cell to selectively engage MHC class II HLA-DR on the surface of the cell in an amount effective to decrease mitochondrial membrane potential in the tumor cell.

2. (Previously Amended) The method of claim 1, wherein MHC class II HLA-DR is expressed on the surface of the tumor cell.

3. (Currently Amended) The method of claim 1, further comprising the step of contacting the tumor cell with an amount of an MHC class II HLA-DR inducing agent effective to induce the expression of MHC class II HLA-DR on the surface of the tumor cell, wherein the MHC class II HLA-DR inducing agent is a UCP expression vector or a TCR$\alpha\beta$ engagement molecule.

4. (Previously Amended)The method of claim 3, wherein the MHC class II HLA-DR ligand is administered to the tumor cell *in vivo* in an amount effective for causing cell lysis of the tumor cell, and wherein the MHC class II HLA-DR inducing agent does not include adriamycin and gamma interferon.

5-7. (Cancelled)

8. (Original) The method of claim 3, wherein the MHC class II HLA-DR ligand is an anti-MHC class II HLA-DR antibody.

9. (Original) The method of claim 3, wherein the MHC class II HLA-DR ligand is selected from the group consisting of CD4 molecules, αβ T cell receptor molecules, γδ T cell receptor molecules and a MHC class II HLA-DR binding peptide.

10. (Original) The method of claim 3, wherein the MHC class II HLA-DR inducing agent and the MHC class II HLA-DR ligand are administered simultaneously.

11. (Original) The method of claim 3, wherein the MHC class II HLA-DR inducing agent and the MHC class II HLA-DR ligand are administered orally.

12. (Original) The method of claim 3, wherein the MHC class II HLA-DR inducing agent and the MHC class II HLA-DR ligand are administered locally.

13. (Original) A method for decreasing mitochondrial membrane potential in a mammalian cell, comprising

contacting the mammalian cell with an amount of an MHC class II HLA-DR inducing agent effective to induce the expression of MHC class II HLA-DR on the surface of the mammalian cell, wherein the mammalian cell is not an antigen presenting cell.

14-38. (Cancelled)

39. (Currently Amended) A method for decreasing mitochondrial membrane potential in a tumor cell, <u>expressing MHC class II HLA-DR on the surface</u>, of a subject, comprising

administering an MHC class II HLA-DR ligand to the subject to selectively engage MHC class II HLA-DR on the surface of the tumor cell in an amount effective to decrease mitochondrial membrane potential in the tumor cell.

40 – 43. (Cancelled)

44. (Currently Amended) A method for inducing the expression of immune recognition molecules on a cell surface, comprising

contacting a cell with an amount of a metabolic inhibition agent effective to decrease mitochondrial membrane potential, wherein a decrease in mitochondrial membrane potential causes induction of the expression of immune recognition molecules on the cell surface, wherein the metabolic inhibition agent is selected from the group consisting of apoptotic chemotherapeutic agents, bacterial byproducts, mycobacterial antigens, and UCP expression vectors.

45 – 142. (Cancelled)

143. (Previously Added) The method of claim 39, wherein the method is performed *in vivo*.

144. (Previously Added) The method of claim 39, wherein the method is performed *ex vivo*.

145-146. (Cancelled)

147. (Previously Added) The method of claim 44, wherein the immune recognition molecule is selected from the group consisting of MHC Class II, b7-1, b7-2, and CD-40.

148. (Canceled).